CIRCULATING SURVIVIN-POSITIVE EXOSOMES
First Claim
1. A method for evaluating the efficacy of a therapy in an individual being treated for glioma comprising:
- (i) determining a reference circulating level of exosomes that are positive for CD9, a glial marker, and survivin (CD9+/Glial marker+/SVN+ exosomes), (ii) at selected time during therapy, determining whether the level of circulating CD9+/Glial marker+/SVN+ exosomes in the individual is at or below the reference level, said determination indicating that the therapy is efficacious; and
(iii) continuing the therapy in the individual having a level of CD9+/Glial marker+/SVN+ exosomes at or below the reference level, or discontinuing or changing the therapy in the individual having a level of CD9+/Glial marker+/SVN+ exosomes above the reference level.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided is a method for evaluating the progression of glioma in an individual comprising monitoring the levels of circulating exosomes that are positive for survivin and a glial marker (such as glial fibrillary acidic protein). An increase in the level of such exosomes is indicative of poor prognosis. Levels of circulating exosomes that are positive for survivin and glial marker can also be used for evaluating the efficacy of a therapy for glioma in an individual, and modifying the therapy or introducing additional therapy if levels of such exosomes are found to be increasing.
-
Citations
15 Claims
-
1. A method for evaluating the efficacy of a therapy in an individual being treated for glioma comprising:
- (i) determining a reference circulating level of exosomes that are positive for CD9, a glial marker, and survivin (CD9+/Glial marker+/SVN+ exosomes), (ii) at selected time during therapy, determining whether the level of circulating CD9+/Glial marker+/SVN+ exosomes in the individual is at or below the reference level, said determination indicating that the therapy is efficacious; and
(iii) continuing the therapy in the individual having a level of CD9+/Glial marker+/SVN+ exosomes at or below the reference level, or discontinuing or changing the therapy in the individual having a level of CD9+/Glial marker+/SVN+ exosomes above the reference level. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- (i) determining a reference circulating level of exosomes that are positive for CD9, a glial marker, and survivin (CD9+/Glial marker+/SVN+ exosomes), (ii) at selected time during therapy, determining whether the level of circulating CD9+/Glial marker+/SVN+ exosomes in the individual is at or below the reference level, said determination indicating that the therapy is efficacious; and
-
11. A method of treating an individual with a glioma comprising:
-
i) surgically removing the glioma; ii) measuring a level of CD9+/Glial marker+/SVN+ exosomes; iii) administering to the individual a composition comprising a peptide of SEQ ID NO;
1;iv) at different times after administration of said composition, determining the level of circulating CD9+/Glial marker+/SVN+ exosomes in the individual; and v) if the circulating levels of CD9+/Glial marker+/SVN+ exosomes are found to be above the reference level, then subjecting the individual to further treatment. - View Dependent Claims (12, 13)
-
-
14. A kit for evaluating the efficacy of a glioma treatment in an individual comprising:
detectably labeled antibodies for CD9+, detectably labeled antibody for a glial marker, detectably labeled antibody for survivin in suitable buffer, and optionally instructions for use of the antibodies for detection of circulating CD9+/Glial marker+/survivin+ exosomes in an individual. - View Dependent Claims (15)
Specification